The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell ...

The checkpoint inhibitor is now approved, based on CheckMate 77T findings, for neoadjuvant/adjuvant use in patients with resectable NSCLC.

The approval was based on data from the randomized, double-blind, placebo-controlled, phase 3 CheckMate -77T trial.

No benefit seen for rechallenge with nivolumab after progression in the post-immune checkpoint inhibitor setting.

When cancer cells mutate, they produce small peptides called neoantigens.  Because neoantigens remain relatively unique to ...

Two strategies to de-escalate treatment for human papillomavirus (HPV)-positive oropharyngeal cancer failed to show ...

Toni Choueiri, MD, discusses the rationale behind the drug combination of tivozanib and nivolumab in the TiNivo-2 study.

Bristol-Myers Squibb (BMY) wins FDA nod to expand the U.S. label for its blockbuster immunotherapy Opdivo in lung cancer.

The Food and Drug Administration has approved Opdivo before and after surgery for some with non-small cell lung cancer.

Nivolumab, an immune checkpoint inhibitor lauded for its groundbreaking approach to cancer treatment, marked its 10th ...

After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...

The NRG Oncology NRG-HN005 phase II/III clinical trial has not met the non-inferiority criteria to proceed to the phase III ...